Association of higher erythropoiesis stimulating agent dose and mortality in children on dialysis

Pediatric Nephrology

Volumn 29, Issue 10, 2014, Pages 2021-2028

  Lestz, Rachel M ^a   Fivush, Barbara A ^b   Atkinson, Meredith A ^b  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anemia; Darbepoetin alfa; Death; Epogen; Hemoglobin

Indexed keywords

ANTIANEMIC AGENT; ERYTHROPOIETIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT PROTEIN;

ANALOGS AND DERIVATIVES; CHILD; COHORT ANALYSIS; FEMALE; HEMODIALYSIS; HUMAN; MALE; MORTALITY; PROPORTIONAL HAZARDS MODEL; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDY;

CHILD; COHORT STUDIES; DARBEPOETIN ALFA; EPOETIN ALFA; ERYTHROPOIETIN; FEMALE; HEMATINICS; HUMANS; MALE; PROPORTIONAL HAZARDS MODELS; RECOMBINANT PROTEINS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES;

EID: 84939890882     PISSN: 0931041X     EISSN: 1432198X     Source Type: Journal    
DOI: 10.1007/s00467-014-2820-9     Document Type: Article

References (30)

1. Amaral S, Hwang W, Fivush B, Neu A, Frankenfield D, Furth S (2006) Association of mortality and hospitalization with achievement of adult hemoglobin targets in adolescents maintained on hemodialysis. J Am Soc Nephrol 17:2878–2885
2. Borzych-Duzalka D, Bilginer Y, Ha IS, Bak M, Rees L, Cano F, Munarriz RL, Chua A, Pesle S, Emre S, Urzykowska A, Quiroz L, Ruscasso JD, White C, Pape L, Ramela V, Printza N, Vogel A, Kuzmanovska D, Simkova E, Muller-Weifel DE, Sander A, Warady BA, Schaefer F (2013) Management of anemia in children receiving chronic peritoneal dialysis. J Am Soc Nephrol 24:665–676
3. Collins AJ, Ma JZ, Ebben J (2000) Impact of hematocrit on morbidity and mortality. Semin Nephrol 20:345–349
4. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A, CREATE Investigators (2006) Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355:2071–2084
5. Foley RN, Parfrey PS, Morgan J, Barre PE, Campbell P, Cartier P, Coyle D, Fine A, Handa P, Kingma I, Lau CY, Levin A, Mendelssohn D, Muirhead N, Murphy B, Plante RK, Posen G, Wells GA (2000) Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 58:1325–1335
6. Furuland H, Linde T, Ahlmen J, Christensson A, Strombom U, Danielson BG (2003) A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant 18:353–361
7. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D, CHOIR Investigators (2006) Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355:2085–2098
8. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA (1998) The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339:584–590
9. KDOQI (2007) KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 50:471–530
10. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R, TREAT Investigators (2009) A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361:2019–2032
11. Kliger AS, Foley RN, Goldfarb DS, Goldstein SL, Johansen K, Singh A, Szczech L (2013) KDOQI US commentary on the 2012 KDIGO clinical practice guideline for anemia in CKD. Am J Kidney Dis 62:849–859
12. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group (2012) KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2:279–335
13. Neu AM, Frankenfield DL (2009) Clinical outcomes in pediatric hemodialysis patients in the USA: lessons from CMS’ ESRD CPM project. Pediatr Nephrol 24:1287–1295
14. United States Renal Data System. 2012 researcher’s guide to the USRDS database. http://www.usrds.org/research.aspx. Updated 2012. Accessed 20 June 2013
15. Amaral S, Hwang W, Fivush B, Neu A, Frankenfield D, Furth S (2008) Serum albumin level and risk for mortality and hospitalization in adolescents on hemodialysis. Clin J Am Soc Nephrol 3:759–767
16. Morgenstern B, Nair KS, Lerner G, Neu A, Quan A, Warady BA, Pediatric Peritoneal Dialysis Study Consortium (2001) Impact of total body water errors on kt/V estimates in children on peritoneal dialysis. Adv Perit Dial 17:260–263
17. Hemodialysis Adequacy 2006 Work Group (2006) KDOQI clinical practice guidelines for hemodialysis adequacy, update 2006. Am J Kidney Dis 48:S2–S90
18. KDOQI (2006) KDOQI clinical practice guidelines for peritoneal dialysis adequacy, update 2006. Am J Kidney Dis 48:S91–S158
19. Zhang Y, Thamer M, Stefanik K, Kaufman J, Cotter DJ (2004) Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis 44:866–876
20. Port RE, Mehls O (2009) Erythropoietin dosing in children with chronic kidney disease: based on body size or on hemoglobin deficit? Pediatr Nephrol 24:435–437
21. Atkinson MA, Furth SL (2011) Anemia in children with chronic kidney disease. Nat Rev Nephrol 7:635–641
22. Foley RN (2008) Erythropoietin: physiology and molecular mechanisms. Heart Fail Rev 13:405–414
23. Badve SV, Hawley CM, Johnson DW (2011) Is the problem with the vehicle or the destination? does high-dose ESA or high haemoglobin contribute to poor outcomes in CKD? Nephrol (Carlton) 16:144–153
24. Staples AO, Wong CS, Smith JM, Gipson DS, Filler G, Warady BA, Martz K, Greenbaum LA (2009) Anemia and risk of hospitalization in pediatric chronic kidney disease. Clin J Am Soc Nephrol 4:48–56
25. Goodkin DA, Fuller DS, Robinson BM, Combe C, Fluck R, Mendelssohn D, Akizawa T, Pisoni RL, Port FK (2011) Naturally occurring higher hemoglobin concentration does not increase mortality among hemodialysis patients. J Am Soc Nephrol 22:358–365
26. Koulouridis I, Alfayez M, Trikalinos TA, Balk EM, Jaber BL (2013) Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis. Am J Kidney Dis 61:44–56
27. Goodnough LT, Nemeth E, Ganz T (2010) Detection, evaluation, and management of iron-restricted erythropoiesis. Blood 116:4754–4761
28. Atkinson MA, White CT (2012) Hepcidin in anemia of chronic kidney disease: review for the pediatric nephrologist. Pediatr Nephrol 27:33–40
29. Zaritsky J, Young B, Wang HJ, Westerman M, Olbina G, Nemeth E, Ganz T, Rivera S, Nissenson AR, Salusky IB (2009) Hepcidin—a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol 4:1051–1056
30. Bamgbola OF, Kaskel FJ, Coco M (2009) Analyses of age, gender and other risk factors of erythropoietin resistance in pediatric and adult dialysis cohorts. Pediatr Nephrol 24:571–579